(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-phenylpropanoic acid

We are (2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-phenylpropanoic acid CAS:3061-90-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-phenylpropanoic acid
CAS.NO: 3061-90-3
Molecular Formula:C12H16N2O3
Molecular Weight:236.26700

Synonyms:
L-ALA-PHE
H-Ala-Phe-OH
L-ala-L-phe
alanylphenylalanine
dipeptide of L-alanine and L-phenylalanine
ALA-PHE
Ala-Phe-OH
L-alanyl-phenylalanine
L-Ala-L-Phe-OH
L-alanyl-L-phenylalanine
H-β-Ala-Phe-OH

Physical and Chemical Properties:
Density: 1.222 g / cm3
Boiling point: 487.6ºC at 760 mmHg
Flash point: 248.7ºC
Refractive index: 1.565

Specification:
Appearance: White  Powder
Purity:≥98%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at -20ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-phenylpropanoic acid


Related News: Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells.Ácido 4-hidroxifenilborónico CAS:71597-85-8 Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more.3-Methylbenzonitrile Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more.3-Ethyl-4-methyl-3-pyrrolin-2-one CAS:766-36-9 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).

Related Products
Product Name
2′,2′-Difluoro-2′-deoxycytidine-3′,5′-dibenzoate View Details
(2S)-beta-Alanyl-L-prolyl-2,4-diamino-N-(phenylmethyl)butanamide acetate View Details
ethyl N-[4-chloro-3-(trifluoromethyl)phenyl]carbamate View Details
(1S,3R,4S,5S)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol manufacturer 2-Amino-5-bromothiazole monohydrobromide manufacturer Tetrabutylammonium fluoride trihydrate manufacturer Fmoc-Nalpha-methyl-O-t-butyl-L-tyrosine manufacturer methyl 2,3-difluoroisonicotinate manufacturer